Clinical Research
Filter News
Found 137,827 articles
-
A trial evaluating generic drugs against severe COVID-19 provided data showing their overall ineffectiveness, and COVID-19-related lawsuits continue to pile up.
-
Cassava Sciences has been informed by the Journal of Prevention of Alzheimer's Disease that there is no evidence to support the charges, the company said Thursday.
-
Curis announced that the FDA has lifted the partial clinical hold on its TakeAim Lymphoma Phase I/II study of emavusertib.
-
Jazz Pharma is breaking new ground with its cannabidiol epilepsy treatment Epidiolex, taking the drug into a Phase III study in children and adolescents.
-
Researchers at Case Western University looked at the real-world experiences of 13,644 patients who were treated with Paxlovid or Lagevrio (molnupiravir) during the first half of 2022.
-
South Korea-based Genuv Inc. announced the publication of a preclinical study showing the potential of Mekinist, approved by the FDA for melanoma, in Alzheimer's disease.
-
Keep reading to take a look at some of the best pharma jobs for travelers. These jobs will allow you to see different parts of the world while working in an exciting and fast-paced industry.
-
Think Bioscience Raises $17M in Oversubscribed Seed Round to Develop Small Molecule Drugs that Hit Undruggable Proteins
8/18/2022
Think Bioscience has raised $17M in an oversubscribed Seed round led by Innovation Endeavors and Xora Innovation, with participation from AV8 Ventures, Buff Gold Ventures, and LiquidMetal Ventures.
-
Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
8/18/2022
Sirnaomics Ltd. announced today that the Company has dosed the first patient in a Phase I/II clinical study of STP705, the Company's leading siRNA (small interfering RNA) drug candidate, for the treatment of patients with facial squamous cell skin cancer in situ (isSCC).
-
Gestalt Diagnostics and Voicebrook Announce Strategic Partnership
8/18/2022
Gestalt Diagnostics and Voicebrook today announced a strategic partnership to benefit information flow and technology interactions in the pathology laboratory.
-
Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate
8/18/2022
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that it has initiated rolling submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of the Company’s single-shot chikungunya vaccine candidate in persons aged 18 years and above.
-
Dermaliq Therapeutics announces first patient dosed in Phase 1b/2 trial evaluating DLQ02 for treatment of plaque psoriasis
8/18/2022
Dermaliq Therapeutics, Inc. today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor.
-
Nordic Nanovector to explore strategic options
8/18/2022
Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") today announces that its Board of Directors (the "Board") has appointed Carnegie Investment Bank ("Carnegie") to explore strategic options available to the Company.
-
Valo Health Announces First Patient Dosed in the OPL-0401 Phase 2 study of an oral ROCK1/2 inhibitor for the Treatment of Non-Proliferative Diabetic Retinopathy
8/18/2022
Valo Health, Inc. today announced that dosing has commenced in its Phase 2 study - a multi-center randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of oral OPL-0401 in patients with mild, moderate, and severe non-proliferative diabetic retinopathy (NPDR).
-
Innovative Cellular Therapeutics (ICT) Announces First Patient Enrolled for the Company’s Phase I Trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer
8/18/2022
Innovative Cellular Therapeutics, Inc. today announced that the first patient has been enrolled in its Phase I trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC).
-
89bio Announces Completion of Enrollment in ENLIVEN, the Phase 2b Trial of Pegozafermin for the Treatment of NASH219 total patients enrolled; topline data expected in the first quarter of 2023
8/18/2022
89bio, Inc. today announced that it has completed enrollment in ENLIVEN, the Phase 2b trial of pegozafermin for the treatment of NASH.
-
Spectral Announces FDA Approval to Add Up to 10 Additional Tigris Clinical Trial Sites
8/18/2022
Spectral Medical Inc. today announced that following a review of Spectral’s supplemental information to its Investigational Device Exemption (IDE) application, the United States Food and Drug Administration (FDA) has approved the addition of up to ten new clinical trial sites to the Company’s pivotal Tigris trial.
-
Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial
8/18/2022
Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the successful completion of safety measures for their Phase I Multi-Day Ascending Dosing (MAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects.
-
FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib
8/18/2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the TakeAim Lymphoma Phase 1/2 study of emavusertib after reviewing the comprehensive data package submitted by Curis.
-
Cell Stress and Mitochondrial Dysfunction Found in Early Alzheimer’s Disease Patients, Findings Published in Science Translational Medicine
8/18/2022
Invicro LLC (Invicro), a global, industry-leading imaging CRO, and a subsidiary of REALM IDx, Inc., today announced the publication of the paper “Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer’s disease 1” in Science Translational Medicine.